Phathom Pharmaceuticals, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.phathompharma.com

Safety Score

Market Cap $167.13M
Debt $203.25M
Cash $212.32M
EV $158.06M
FCF -$282.79M

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$345.79M
EBIT	-$286.38M
ROA	-97%
FCF	-$282.79M
Equity	-$338.38M
Growth Stability	1
PE	-0.48
PB	-0.49
P/FCF	-0.59
P/S	2.04
Price/Cash	1.27
Debt/Equity	-0.6
Debt/FCF	-0.72
Net Margins	-331%
Gross Margins	86%
Op. Margins	-350%
Sales Growth YoY	1K%
Sales Growth QoQ	-4%
Sales CAGR	2%
Equity CAGR	-2%
Earnings Growth YoY	14%

Earnings Growth QoQ	27%
Sales CAGR 5Y	11%
Equity CAGR 5Y	-5%
Earnings CAGR 3Y	320%
Sales CAGR 3Y	320%
Market Cap	$167.13M
Revenue	$81.86M
Assets	$294.21M
Total Debt	$203.25M
Cash	$212.32M
Shares Outstanding	69.64M
EV	158.06M
Safety Score	34%
Working Capital	190.87M
Current Ratio	3.58
Gross Profit	$70.59M
Shares Growth 3y	25%
Equity Growth QoQ	33%
Equity Growth YoY	128%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

SEC Filings

Direct access to Phathom Pharmaceuticals, Inc. (PHAT) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Phathom Pharmaceuticals, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Phathom Pharmaceuticals, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Phathom Pharmaceuticals, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Phathom Pharmaceuticals, Inc..

Years

Calculation mode

= -$2.8B

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	-$283M	-$283M	-$283M	-$283M	-$283M	-$283M	-$283M	-$283M	-$283M	-$283M	-$283M	-$2.8B
DCF		-$257M	-$234M	-$212M	-$193M	-$176M	-$160M	-$145M	-$132M	-$120M	-$109M	-$1.1B
Value	-$2.8B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-	-	-	-	-	-30K%	-605%	-331%
ROA	-	-41%	-43%	-71%	-105%	-40%	-73%	-97%
ROE	-	-112%	-66%	-199%	264%	277%	132%	-

Bad Net Margins (-330.71%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-0.81	-0.67	-0.68	-1.01	-0.75	-0.72
Debt over Equity	-1.52	0.11	0.3	1.39	-1.34	-1.92	-0.79	-0.6
Growth Stability	-	-	-	-	-	-	-	1

Good Debt/FCF ratio (-0.72)

Net Margins are high enough to offer a good protection on the profits in case of higher costs or higher interests. Furthermore higher margins reduce earnings’ volatility.

Good Debt/Equity ratio (-0.6)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	-	-	-	-	8K%	11%
Earnings YoY growth	-	20K%	-49%	11%	37%	2%	66%	-
Equity YoY growth	-	-18K%	-15%	-63%	-204%	-3%	249%	-5%
FCF YoY growth	-	-	93%	111%	-1%	-6%	92%	-